The Oncology Institute

TOI

Market cap $331M

DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the “Company”), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (NASDAQ: TOI).

Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer.

The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point.

CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise.

The Oncology Institute has struck deals to care for cancer patients in five states, which leaves room for growth. It's currently treating nearly 2 million patients.

The Oncology Institute, Inc. ( TOI ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO & Executive Director Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Greetings, and welcome to The Oncology Institute Third Quarter 2025 Earnings Call.

The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.18 per share a year ago.

Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload

CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI),  a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2025 financial results after the market close on Thursday, November 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

Technology stocks get a lot of hype these days. That's particularly true for those involved in generative artificial intelligence.